Huang Ao, Zhang Xin, Zhou Shao-Lai, Cao Ya, Huang Xiao-Wu, Fan Jia, Yang Xin-Rong, Zhou Jian
Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University.
Cancer Research Institute, Central South University.
J Cancer. 2016 Aug 12;7(13):1798-1803. doi: 10.7150/jca.15618. eCollection 2016.
The clinical significance of circulating cell-free DNA (cfDNA) integrity as diagnostic and surveillance biomarker in hepatocellular carcinoma (HCC) was investigated and compared to that of alpha fetoprotein (AFP). Liver cancer patients had lower cfDNA integrity than those with benign diseases ( = 0.0167) and healthy individuals ( = 0.0025). Patients with HCC and non-HCC liver cancers ( = 0.7356), and patients with benign diseases and healthy individuals ( = 0.9138) had comparable cfDNA integrity respectively. cfDNA integrity increased after hepatectomy in cancer patients ( = 0.0003). The AUCs for detecting HCC by cfDNA integrity and AFP were 0.705 ( = 0.005) and 0.605 ( = 0.156), respectively. We found cfDNA integrity decreased in HCC patients and has the potential as promising biomarker for HCC diagnosis and treatment surveillance.
研究了循环游离DNA（cfDNA）完整性作为肝细胞癌（HCC）诊断和监测生物标志物的临床意义，并与甲胎蛋白（AFP）进行了比较。肝癌患者的cfDNA完整性低于良性疾病患者（P = 0.0167）和健康个体（P = 0.0025）。HCC患者和非HCC肝癌患者（P = 0.7356）以及良性疾病患者和健康个体（P = 0.9138）的cfDNA完整性分别具有可比性。癌症患者肝切除术后cfDNA完整性增加（P = 0.0003）。通过cfDNA完整性和AFP检测HCC的AUC分别为0.705（P = 0.005）和0.605（P = 0.156）。我们发现HCC患者的cfDNA完整性降低，并且有潜力作为HCC诊断和治疗监测的有前景的生物标志物。
